Monday, July 09, 2007 7:39:30 AM
ViaCell, Inc. (Nasdaq: VIAC) announced today that it has received FDA approval of its investigational device exemption (IDE) supplement for its ViaCyteSM pivotal clinical trial. The pivotal study will evaluate ViaCyte, an investigational product being studied for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. FDA approval of the IDE supplement allows the Company to enroll women into the study and commence in vitro fertilization treatment, or IVF. Previously, the FDA disapproved the IDE supplement. In doing so, the FDA asked ViaCell to respond to questions related to the specifications and sourcing of certain raw materials used in the manufacturing of the ViaCyte media. All questions have been addressed and no conditions are outstanding.
“We are extremely pleased we resolved this issue with the FDA,” said Karen Nichols, Vice President, Regulatory Affairs and Quality Systems at ViaCell. “We can now begin treatment of women previously consented to participate in the ViaCyte pivotal trial and we expect our U.S. sites to advance enrollment. We continue to expect to complete the trial in 2009.”
The primary objective of the pivotal study is to determine the efficacy of the ViaCyte media for the cryopreserving and thawing of human oocytes. The open-label study will also evaluate safety. Women seeking IVF, diagnosed with male factor infertility, are eligible to enroll. The primary efficacy endpoint is live birth rate and 50 live births must be achieved. Participants in the study will undergo traditional IVF. After the eggs are retrieved, oocyte cryopreservation will be performed using ViaCyte. The oocytes will be thawed following storage in liquid nitrogen and subsequently inseminated. Embryos will be transferred to the subject’s uterus using a non-surgical procedure. Additional information about the trial is available online at http://www.clinicaltrials.gov.
About ViaCyte
ViaCyte is an investigational product intended to broaden reproductive options for women through the cryopreservation and thawing of human oocytes. The oocyte is a large cell with a high content of water, historically making it difficult to freeze. ViaCell’s proprietary technology to cryopreserve and thaw human oocytes uses a choline chloride-based media designed to protect the cells from damage during the freezing process with the goal of making it possible to successfully store and thaw oocytes for future use. There is currently no FDA-cleared product for oocyte cryopreservation.
About ViaCell
ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.
This press release contains forward-looking statements regarding the clinical development of ViaCyte, including ViaCell’s expectations as to the completion of the ViaCyte clinical trial. Such statements are based on management's current expectations. Successful and timely completion of the ViaCyte clinical trial are subject to a number of risks and uncertainties which could cause actual results to differ materially from the Company’s current expectations. For example, there is no assurance that the results of the clinical trial will show that ViaCyte is safe and effective in the preservation and storage of oocytes. ViaCell may not be able to enroll a sufficient number of patients in the clinical trial or to enroll patients as rapidly as it expects. ViaCell may not be able to generate a sufficient number of live births. ViaCell may encounter safety issues. Manufacturing the ViaCyte media is a complex process. ViaCell may be unable to have the ViaCyte media consistently manufactured to specifications. Even if the data from the clinical trial is positive, there is no assurance that the FDA will agree that ViaCell has met the standards for 510(k) clearance, ViaCell’s specified regulatory pathway for ViaCyte. The FDA could at any time determine that ViaCyte will require pre-marketing authorization, which would involve additional trials, time and expense. There is no assurance that the FDA will ever approve the product. Even if approved, there is no assurance that ViaCyte will achieve commercial success or be able to successfully compete with other oocyte cryopreservation and IVF products. Drug and device development involves a high degree of risk. For more information on the risks and uncertainties associated with the Company and its products and programs, see the factors set forth under the heading “Risk Factors” in the Company’s report on Form 10-Q for the quarter ending March 31, 2007, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.
ViaCell® and ViaCord® are federally registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.
ViaCell, Inc.
Justine E. Koenigsberg, 617-914-3494
Senior Director, Corporate Communications
Source: Business Wire (July 9, 2007 - 7:31 AM EDT)
Recent PARA News
- Futures Pointing To Roughly Flat Open On Wall Street • IH Market News • 05/07/2024 01:09:12 PM
- U.S. Stocks See Further Upside Amid Renewed Interest Rate Optimism • IH Market News • 05/06/2024 08:34:36 PM
- Perficient Stock Soars 52.9% Post-Acquisition; Luminar Declines 10% Amid Workforce Cutbacks, and Other News • IH Market News • 05/06/2024 12:09:00 PM
- IHOP® Brings Imagination to Life With the Launch of the New Menu Inspired by Paramount Pictures’ New Movie IF • Business Wire • 05/06/2024 12:00:00 PM
- 456 BILLION MINUTES OF CBS PROGRAMMING WATCHED IN THE FIRST FOUR MONTHS OF 2024 • PR Newswire (US) • 05/02/2024 03:38:00 PM
- HSBC’s High Profit & CEO Resignation, Santander’s 11% Profit Surge, and More in Earnings • IH Market News • 04/30/2024 11:55:21 AM
- Paramount Global Reports First Quarter Earnings Results • PR Newswire (US) • 04/29/2024 08:02:00 PM
- PARAMOUNT GLOBAL ANNOUNCES NEW LEADERSHIP • PR Newswire (US) • 04/29/2024 08:00:00 PM
- U.S. Futures Rise in Pre-Market Trading Amid Key Federal Reserve Meeting and Earnings Week Ahead • IH Market News • 04/29/2024 11:12:54 AM
- Philips Stocks Soar 47% Following US Deal, Tesla Bolsters Presence in China, and More News • IH Market News • 04/29/2024 11:11:24 AM
- PARAMOUNT+ RENEWS ORIGINAL ANIMATED PRESCHOOL SERIES DORA FOR A SECOND SEASON • PR Newswire (US) • 04/24/2024 02:00:00 PM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News • IH Market News • 04/15/2024 11:06:48 AM
- Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News • IH Market News • 04/12/2024 11:05:29 AM
- Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News • IH Market News • 04/11/2024 11:24:54 AM
- Paramount Global Declares Quarterly Cash Dividend • PR Newswire (US) • 04/10/2024 08:15:00 PM
- Paramount Global to Report First Quarter Financial Results on April 29, 2024 • PR Newswire (US) • 04/09/2024 08:15:00 PM
- Shopsense AI Launches Retail Media Platform for Broadcasters • Business Wire • 04/05/2024 12:00:00 PM
- Exxon Mobil Forecasts Earnings Decline, Twilio Seeks Board Tenure Changes, and More News • IH Market News • 04/04/2024 11:30:20 AM
- Cal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and More • IH Market News • 04/03/2024 11:12:20 AM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- NICKELODEON SERVES UP BRAND-NEW EPISODES OF THE TINY CHEF SHOW BEGINNING MONDAY, APRIL 8 • PR Newswire (US) • 03/25/2024 03:00:00 PM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- PARAMOUNT+ ANNOUNCES LAUNCH TIMING AND PRICING FOR INTERNATIONAL ADVERTISING-SUPPORTED & PREMIUM SUBSCRIPTION PLANS • PR Newswire (Canada) • 03/19/2024 01:05:00 PM
- Paramount Global's Chief Financial Officer Naveen Chopra to Participate in the 2024 Morgan Stanley Technology, Media & Telecom Conference • PR Newswire (US) • 02/29/2024 09:15:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM